NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 160 filers reported holding NEVRO CORP in Q1 2023. The put-call ratio across all filers is 0.53 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,808,847 | -31.4% | 198,171 | -9.3% | 0.06% | -22.8% |
| Q2 2023 | $5,556,126 | -29.7% | 218,573 | 0.0% | 0.08% | -31.3% |
| Q1 2023 | $7,901,414 | -23.5% | 218,573 | -16.2% | 0.12% | -16.1% |
| Q4 2022 | $10,329,066 | -15.0% | 260,835 | 0.0% | 0.14% | -21.3% |
| Q3 2022 | $12,155,000 | +4.5% | 260,835 | -1.7% | 0.17% | +6.1% |
| Q2 2022 | $11,630,000 | -32.4% | 265,339 | +11.6% | 0.16% | -18.0% |
| Q1 2022 | $17,203,000 | -10.8% | 237,841 | 0.0% | 0.20% | +0.5% |
| Q4 2021 | $19,282,000 | -22.9% | 237,841 | +10.6% | 0.20% | -21.7% |
| Q3 2021 | $25,017,000 | -17.6% | 214,956 | +17.3% | 0.25% | -14.2% |
| Q2 2021 | $30,373,000 | +20.3% | 183,201 | +1.2% | 0.30% | +10.9% |
| Q1 2021 | $25,251,000 | +11.9% | 181,013 | +38.8% | 0.27% | +3.1% |
| Q4 2020 | $22,573,000 | +34.4% | 130,402 | +8.2% | 0.26% | +11.6% |
| Q3 2020 | $16,795,000 | +25.8% | 120,569 | +7.9% | 0.23% | +22.8% |
| Q2 2020 | $13,352,000 | +67.1% | 111,762 | +39.9% | 0.19% | +21.9% |
| Q1 2020 | $7,989,000 | -38.0% | 79,906 | -27.2% | 0.16% | -24.0% |
| Q4 2019 | $12,895,000 | +3.4% | 109,705 | -24.4% | 0.20% | -12.1% |
| Q3 2019 | $12,475,000 | +36.9% | 145,111 | +3.2% | 0.23% | +48.7% |
| Q2 2019 | $9,112,000 | +13.5% | 140,548 | +9.5% | 0.16% | -64.7% |
| Q1 2019 | $8,026,000 | +153.4% | 128,402 | +57.7% | 0.44% | +112.5% |
| Q4 2018 | $3,167,000 | -30.9% | 81,438 | +1.3% | 0.21% | -28.5% |
| Q3 2018 | $4,584,000 | +122.5% | 80,415 | +211.7% | 0.29% | +65.3% |
| Q2 2018 | $2,060,000 | +122.2% | 25,798 | +141.1% | 0.18% | +91.3% |
| Q1 2018 | $927,000 | +25.4% | 10,700 | 0.0% | 0.09% | +19.5% |
| Q4 2017 | $739,000 | -24.0% | 10,700 | 0.0% | 0.08% | -24.5% |
| Q3 2017 | $972,000 | +34.6% | 10,700 | +10.3% | 0.10% | +20.0% |
| Q2 2017 | $722,000 | -11.4% | 9,700 | +11.5% | 0.08% | -22.0% |
| Q1 2017 | $815,000 | +29.0% | 8,700 | 0.0% | 0.11% | -15.5% |
| Q4 2016 | $632,000 | -19.3% | 8,700 | +16.0% | 0.13% | -8.5% |
| Q3 2016 | $783,000 | +41.6% | 7,500 | 0.0% | 0.14% | +35.6% |
| Q2 2016 | $553,000 | +31.0% | 7,500 | 0.0% | 0.10% | +35.1% |
| Q1 2016 | $422,000 | – | 7,500 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |